Rituximab Pregnancy and Breastfeeding Warnings
Rituximab is also known as: Rituxan
Rituximab Pregnancy Warnings
Reproduction studies in cynomolgus monkeys at maternal exposures similar to human therapeutic exposures showed no evidence of teratogenic effects. There are no controlled data in human pregnancy. There are no data on whether rituximab can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity. Rituximab was detected postnatally in the serum of infants exposed in-utero. Postmarketing data indicate that B-cell lymphocytopenia generally lasting less than six months can occur in infants exposed to rituximab in-utero. Rituximab is only recommended for use in pregnant women if the potential benefit to the mother justifies the potential risk to the fetus. The manufacturer has recommended that individuals of childbearing potential use effective contraceptive methods during treatments and for up to 12 months following therapy with rituximab. There has been a case reported of a pregnant woman who used rituximab in combination with CHOP chemotherapy for aggressive B-cell non-Hodgkin's lymphoma. She delivered a healthy girl via caesarean section in the thirty-fifth week of her pregnancy. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
FDA pregnancy category: C Use rituximab only if clearly needed and benefit outweighs risk.
Rituximab Breastfeeding Warnings
Use of rituximab is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Unknown The effects in the nursing infant are unknown.
Because human IgG is excreted into human milk and the potential for absorption and immunosuppression in the infant are unknown, breast-feeding is not recommended until circulating drug levels are no longer detectable.
References for breastfeeding information
- "Product Information. Rituxan (rituximab)." Genentech, South San Francisco, CA.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.